Skip to main content
. 2022 Jun 30;6(6):851–861. doi: 10.1002/ags3.12593

TABLE 2.

Comparison of patient backgrounds between the DPPHR and PD groups after propensity score matching

DPPHR (n = 25) PD (n = 25) P‐value
Preoperative variables
Age (y) 62.8 ± 11.3 64.2 ± 10.6 .698
Gender (male/female) 15/10 16/9 .771
Body mass index 21.0 ± 3.0 23.1 ± 3.3 .064
Diagnosis (IPMN/NEN/SPN/SCN/others) 20/4/1/0/0 21/2/0/1/1 .151
CT attenuation value (HU) 57.8 ± 5.7 61.8 ± 7.6 .128
Albumin 4.2 ± 0.31 4.3 ± 0.4 .651
Total lymphocyte count 1524 ± 532 1675 ± 653 .378
Hemoglobin 13.7 ± 1.5 13.4 ± 1.3 .289
Prognostic nutrition index 47.5 ± 10.7 49.9 ± 4.8 .698
Aspartate aminotransferase (AST) (IU/L) 23.4 ± 10.7 21.4 ± 6.4 .425
Alanine transaminase (ALT) (IU/L) 20.0 ± 8.7 19.3 ± 6.9 .992
Platelet count (103/μL) 207 ± 66 234 ± 122 .248
FIB‐4 index 1.72 ± 0.68 1.63 ± 0.98 .327
Intraoperative variables
Operative time (min) 447 ± 80 491 ± 237 .788
Blood loss (g) 375 ± 323 327 ± 264 .549
Postoperative variables
Clinically relevant pancreatic fistula (%) 16.0% (4/25) 28.0% (7/25) .306
Complication with Clavien–Dindo grade ≥3 (%) 28% (7/25) 40% (10/25) .370
Postoperative exocrine enzyme supplementation (yes/no) 25/0 23/2 .478

Abbreviations: DPPHR, duodenum‐preserving pancreatic head resection; Fib‐4:Fibrosis‐4; HU, Hounsfield Unit; IPMN, intraductal papillary mucinous neoplasm; NEN, neuroendocrine neoplasm; PD, pancreaticoduodenectomy; SCN, serous cystic neoplasm; SPN, solid pseudopapillary neoplasm.